Glaukos Corporation Announces Second Quarter 2018 Financial Results

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the second quarter ended June 30, 2018. Key highlights include: Achieved 5% net sales growth to $43.2 million in the second quarter of 2018, compared to $41.3 millio

Full Story →